Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): Final results of the ROSORC trial

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 2967-2971

  Procopio, G ^a   Verzoni, E ^a   Bracarda, S ^b   Ricci, S ^c   Sacco, C ^d   Ridolfi, L ^e   Porta, C ^f   Miceli, R ^a   Zilembo, N ^a   Bajetta, E ^g  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g Policlinico of Monza   (Italy)

Author keywords

First line treatment; Interleukin 2; Renal cell carcinoma; Sorafenib; Targeted therapies

Indexed keywords

AXITINIB; EVEROLIMUS; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

FIRST-LINE TREATMENT; INTERLEUKIN-2; RENAL CELL CARCINOMA; SORAFENIB; TARGETED THERAPIES;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84888785384     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt375     Document Type: Article

References (17)

1. Procopio G, Verzoni E, Bracarda S et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011; 104: 1256-1261.
2. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-1939.
3. Motzer RJ, Escudier B, Tomczak P et al. Axitinib vs sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors. Ann Oncol 2012; 23(suppl. 9): ix258-ix293.
4. Hutson T. Temsirolimus versus sorafenib as second-line therapy in patients with advanced rcc who have failed first-line sunitinib (INTORSECT). Ann Oncol 2012; 23(Suppl 9): ixe1-ix30.
5. Motzer R, Eisen T, Hutson TE et al. Overall survival results from a phase 3 study of tivozanib hydrochloride vs sorafenib in patients with renal cell carcinoma. Pro ASCO GU 2013; abs 350: 189.
6. Procopio G, Verzoni E, de Braud F. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma. Oncology 2013; 84: 39-42.
7. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
8. Simon RM, Steinberg SM, Hamilton M et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19: 1848-1854.
9. Evans S, Day S, Royston P. 2010. Minim program. Available at: http://www-users. york.ac.uk/~mb55/guide/minim.htm (14 September 2010, date last accessed).
10. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-461.
11. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-241.
12. Durrleman S, Simon R. Flexible regression models with cubic spines. Stat Med 1989; 8: 551-561.
13. Lamuraglia M, Escudier B, Chami L et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42:2472-2479.
14. Maksimovic O, Schraml C, Hartmann JT et al. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol 2010; 194: 5-14.
15. Iacovelli R, Cartenì G, Sternberg C et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 2013; 49: 2134-2142.
16. Stenner F, Chastonay R, Liewen H et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology 2012; 82: 333-340.
17. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.